Cash Flow Statement

Amortization Amortization Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Mereo BioPharma (MREO) Other financing activities (2024 - 2025)

Mereo BioPharma has reported Other financing activities over the past 2 years, most recently at $134000.0 for Q2 2025.

Quarterly Other financing activities fell 86.6% to $134000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $134000.0 through Mar 2026, down 92.11% year-over-year, with the annual reading at $199000.0 for FY2025, 76.67% down from the prior year.
Other financing activities was $134000.0 for Q2 2025 at Mereo BioPharma, up from $65000.0 in the prior quarter.
Over five years, Other financing activities peaked at $1.0 million in Q2 2024 and troughed at $40000.0 in Q4 2024.